Co-Diagnostics Inc.
CODX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CODX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CODX
Co-Diagnostics Inc. is a molecular diagnostics company focused on developing and commercializing PCR-based testing technologies, including its proprietary Co-Dx PCR platform, with a history of revenue from its Logix Smart COVID-19 test.
Key risk: Limited cash runway
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Co-Diagnostics Inc. is a molecular diagnostics company focused on developing and commercializing PCR-based testing technologies, including its proprietary Co-Dx PCR platform, with a history of revenue from its Logix Smart COVID-19 test.
- Cash and equivalents of $3.6M as of 2026-06-30 [sec].
- Total revenue of $0.2M for the six months ended June 30, 2026 [sec].
- Net loss of $6.3M for the six months ended June 30, 2026 [sec].
- Shareholders' equity of $20.6M as of 2026-06-30 [sec].
- Research and development expenses increased to $5.9M for Q1 2026, driven by clinical trials for the Co-Dx PCR platform [sec_mda · as of 2026-05-14].
What works
- The company has raised capital through stock issuances, with net cash provided by financing activities of $7.1M for the six months ended June 30, 2026, including proceeds from an ATM and a private placement [sec_mda · as of 2026-08-13].
- Co-Diagnostics is investing in its proprietary Co-Dx PCR platform, with clinical trial expenses driving R&D growth, indicating a focus on future product development [sec_mda · as of 2026-05-14].
What to weigh
- The company reported a net loss of $15.4M for the six months ended June 30, 2026, compared to $15.3M for the same period in 2025, with losses driven by decreased other income and increased R&D costs [sec_mda · as of 2026-08-13].
- Revenue remains low at $0.2M for the six months ended June 30, 2026, reflecting a decline from prior COVID-19 test sales and limited commercial traction for new products [sec].
- Cash and equivalents of $3.6M as of 2026-06-30 are limited relative to ongoing operating losses, and the company may need additional financing to sustain operations [sec_mda · as of 2026-03-31].
From the filings
Quoted directly from source documents.
Net loss for the six months ended June 30, 2026 was $15.4 million.
“Net loss for the six months ended June 30, 2026 was $15.4 million, compared to $15.3 million for the six months ended June 30, 2025.”
SEC MD&A · August 13, 2026
Research and development expenses increased due to clinical trials for the Co-Dx PCR platform.
“The increase was primarily a result of expenses related to clinical trials for the Co-Dx PCR platform, partially offset by decreased personnel related expense.”
SEC MD&A · May 14, 2026
The company raised capital through stock issuances in the first half of 2026.
“The cash provided by financing activities during 2026 relates to issuances of common stock under the ATM and proceeds related to a private placement transaction.”
SEC MD&A · August 13, 2026
The company may need additional financing for strategic opportunities.
“Our available capital resources may be consumed more rapidly than currently expected and we may need or want to raise additional financing for strategic opportunities.”
SEC MD&A · March 31, 2026
Risks & what to watch (3)›
Key risks
- Limited cash runway — Cash of $3.6M as of 2026-06-30 may be insufficient to fund operations without additional financing [sec].
- Dependence on Co-Dx platform success — Revenue is minimal, and the company's future depends on successful development and commercialization of the Co-Dx PCR platform [sec_mda · as of 2026-05-14].
- Ongoing net losses — Net loss of $15.4M for H1 2026 indicates persistent unprofitability [sec_mda · as of 2026-08-13].
What to watch
- Progress and outcomes of clinical trials for the Co-Dx PCR platform [sec_mda · as of 2026-05-14].
- Ability to raise additional capital through stock offerings or other means [sec_mda · as of 2026-08-13].
- Any regulatory approvals or commercial partnerships for the Co-Dx platform [sec_mda · as of 2026-03-31].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Co-Diagnostics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Co-Diagnostics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
1.7 months
D/E 0.31 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
7
Total value held
$354
| Holder | Shares | Value |
|---|---|---|
| morgan stanley | 88 | $164 |
| wells fargo & company/mn | 81 | $151 |
| osaic holdings, inc. | 10 | $18 |
| danske bank a/s | 7 | $13 |
| harbour investments, inc. | 2 | $4 |
| citigroup inc | 1 | $2 |
| vanguard fiduciary trust co | 1 | $2 |
Short Interest
as of May 20, 2026- % of float
- 2.7%
- Days to cover
- 0.7
- Shares short
- 94,771
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CODX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Co-Diagnostics Inc.?
Co-Diagnostics Inc. is a molecular diagnostics company focused on developing and commercializing PCR-based testing technologies, including its proprietary Co-Dx PCR platform, with a history of revenue from its Logix Smart COVID-19 test.
Who is the CEO of Co-Diagnostics Inc.?
Mr. Dwight H. Egan is the chief executive officer of Co-Diagnostics Inc. (CODX).
Where is Co-Diagnostics Inc. headquartered?
Co-Diagnostics Inc. (CODX) is headquartered in Salt Lake City, UT, United States.
What therapeutic areas does Co-Diagnostics Inc. focus on?
Co-Diagnostics Inc. develops therapies across Neurology, Immunology, Ophthalmology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.